The Factor V Leiden Mutation which Predisposes to Thrombosis Is Not Common in Patients with Antiphospholipid Syndrome

Summary

Antiphospholipid syndrome is associated with venous, arterial, and placental thrombosis, possibly through autoantibody impairment of phospholipid-dependent protein C activation. Recently, a missense mutation in the factor V gene (1691 G → A) has been identified that results in an abnormal factor V product (1). This mutation, known as the Leiden mutation, causes an amino acid substitution of glutamine for arginine at position 506 in the factor V molecule and renders the protein resistant to proteolytic inactivation by activated protein C and thus predisposes to thrombosis (2, 3). We hypothesized that some individuals with antiphospholipid syndrome may also carry the Leiden mutation, and thus have a “second hit” predisposition to thrombosis. To test this hypothesis, allele-specific hybridization and allele-specific restriction analysis were used to test for the Leiden mutation in thirty women with the antiphospholipid syndrome, 10 of whom had a history of thrombosis. None of the women were heterozygous or homozygous for the factor V mutation. We conclude that the presence of the factor V Leiden mutation is not a prerequisite for the thrombotic events in patients with antiphospholipid syndrome, due to the occurrence of thrombosis seen in patients lacking the factor V mutation.

• References

• 1 Bertina RM, Koeleman BP C, koster T, Rosendaal FR, Dirvcn RJ, tie Ronde H, van der Velden PA, Reilsma PH. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994; 369: 64-67
• 2 Dahlbäck B. Inherited resistance to activated protein C, a major cause of venous thrombosis, is due to a mutation in the factor V gene. Haemostasis 1994; 24: 139-151
• 3 Svensson PJ, Dahlbäck B. Resistance to activated protein C as a basis for venous thrombosis. New Engl J Med 1994; 330: 517-522
• 4 Alarcon-Segovia D, Deleze M, Oria C, Sanchez-Guerrero J, Gomez-Pan-checo L, Cabiedes J, Fernandez L, Ponce de Leon S. Antiphospholipid antibodies and the antiphospholipid syndrome in systemic lupus erythematosus. A prospective study of 500 consecutive cases Medicine 1989; 68: 353-363
• 5 Asherson RA, Khamashta MA, Ordi-Ros J, Derksen RH W M, Machin SJ, Barquinero J, Outt HH, Harris EN, Vilardell-Torres M, Hughes GR V. The “primary” Antiphospholipid Syndrome: major clinical and serological features. Medicine 1989; 68: 366-374
• 6 Silver RM, Branch DW. Should you treat women who have antiphospholipid syndrome. Con Obstet Gynecol 1994; 39: 63-83
• 7 Cariou R, Tobelem G, Soria C, Caen J. Inhibition of protein C activation by endothelial cells in the presence of lupus anticoagulant. N Engl J Med 1986; 314: 1193-1194
• 8 Borrell M, Sala N, de Castellarnau C, Lopez S, Gari M, Fontcuberta J. Immunoglobulin fractions isolated from patients with antiphospholipid antibodies prevent the inactivation of factor Va by activated protein C on human endothelial cells. Thromb Haemost 1992; 68: 268-272
• 9 Marciniak E, Romond EH. Impaired catalytic function of activated protein C: a new in vitro manifestation of lupus anticoagulant. Blood 1989; 74: 2426-2432
• 10 Malia RG, Kitchen S, Greaves M, Preston FF. Inhibition of activated protein C and its cofactor protein S by antiphospholipid antibodies. Br J of Haematology 1990; 76: 101-107
• 11 Fsmon CT. The roles of protein C and thrombomodulin in the regulation of blood coagulation. J Biol Chem 1989; 264: 4743-4746
• 12 Dahlbäck B, Stenflo J. The protein C anticoagulant system. In: The molecular basis of blood diseases. Stamatoyannopoulos G, Nicnhuis AW, Majeurs PW, Various II. eds Philadelphia: Saunders; 1994: 599-628
• 13 Dahlbiick B. Protein S and C4b binding protein: components involved in the regulation of the protein C anticoagulant system. Thromb Haemost 1991; 66: 49-61
• 14 Kalafatis M, Rand MD, Mann KG. The mechanism of inactivation of human factor V and human factor Va by activated protein C. J Biol Chem 1994; 269: 31869-31880
• 15 Branch DW, Silver RM, Blackwell JL, Reading JC, Scott JR. Outcome of treated pregnancies in women with antiphospholipid syndrome: an update of the Utah experience. Obstet Gynecol 1992; 4: 614-620
• 16 Harris EN. Syndrome of the black swan. Br J Rheumatol 1986; 25: 324-326
• 17 Harris EN. A reassessment of the antiphospholipid syndrome. J Rheumatol 1990; 17: 733-735
• 18 Out HJ, Kooijman CD, Bruinse HW, Derksen RH W M. Histo-pathological findings from patients with intrauterine fetal death and antiphospholipid antibodies. Eur J Obstet Gynecol 1991; 41: 179-186
• 19 Johansson EA, Niemi KM, Hustakillis KK. A peripheral vascular syndrome overlapping with systemic lupus erythematosus. Recurrent venous thrombosis and hemorrhagic capillary proliferation with circulating anticoagulants and false positive seroreactions for syphilis Dermatologica 1977; 155: 257
• 20 Harris EN, Bos K. An acute disseminated coagulopathy-vasculopathy associated with the antiphospholipid syndrome. Arch Intern Med 1991; 151: 231-233
• 21 Lockwood CJ, Romero R, Feinberg RF, Clyne LP, Coster B, Hobbins JC. The prevalence and biologic significance for lupus anticoagulant and anticardiolipin antibodies in a general obstetric population. Am J Obstet Gynecol 1989; 161: 369-373
• 22 Harris EN, Spinnato JA. Should anticardiolipin tests be performed in otherwise healthy pregnant women. Am J Obstet Gynecol 1991; 165: 1272-1277
• 23 Vandenbroucke JP, Koster T, Briet E, Reitsma PH, Bertina RM, Rosendaal FR. Increased risk of venous thrombosis in oral-contraceptive users who are carriers of factor V Leiden mutation. Lancet 1994; 344: 1453-1457
• 24 Koeleman BP C, Reitsma PH, Allaart CF, Bertina RM. Activated protein C resistance as an additional risk factor for thrombosis in protein C-deficient families. Blood 1994; 84: 1031-1035
• 25 McLellan T, Jorde LB, Skolnick MH. Genetic distances between the Utah Mormons and related populations. Am J Hum Genet 1984; 36: 836-857
• 26 Jorde LB. Inbreeding in the Utah Mormons: an evaluation of estimates based on pedigrees, isonymy, and migration matrices. Ann Hum Genet 1989; 53: 339-355